• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Perinat Med . Initial review of pregnancy and neonatal outcomes of pregnant women with COVID-19 infection

tetano

Editor, Senior Moderator
J Perinat Med


. 2020 Nov 3;/j/jpme.ahead-of-print/jpm-2020-0446/jpm-2020-0446.xml.
doi: 10.1515/jpm-2020-0446. Online ahead of print.
Initial review of pregnancy and neonatal outcomes of pregnant women with COVID-19 infection


Ifeoma Ogamba[SUP] 1 [/SUP], Andrea Kliss[SUP] 1 [/SUP], Nicole Rainville[SUP] 1 [/SUP], Linus Chuang[SUP] 2 [/SUP], Erin Panarelli[SUP] 1 [/SUP], Joann Petrini[SUP] 1 [/SUP], Dimitry Zilberman[SUP] 2 [/SUP]



Affiliations

Abstract

Objectives Data regarding the pathogenesis and clinical manifestations of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continue to emerge, however, there's limited data in regard to maternal and neonatal outcomes. Therefore, we conducted a retrospective analysis of all pregnant women who tested positive for SARS-CoV-2 within Nuvance Health system. Study design Data were abstracted from the medical records of each patient and descriptive analysis was performed. Variables included demographics, COVID testing results, symptoms, management, labor course, neonatal information, and complications. Results Total of 40 patients were identified. Average age was 29.6 years old, 35% were Hispanic, and approximately one in three patients had comorbidities. Of the patients who had repeated testing, the average number of days between first positive test and negative test was 36.8 days (+/- 19.9 days). Three out of four women reported symptoms. Of the 40 pregnant women who were positive for SARS-CoV-2, 25 of them delivered. About 84% of the women delivered after 37 weeks. Twelve percent of the women delivered under 33 and 6/7 weeks. Most patients had vaginal deliveries (68%) and the remaining had cesarean deliveries. Neonatal outcomes included: mean 1 and 5 min Apgar scores of 8 and 8.8, respectively and the mean birth weight was 3212 g. Twenty neonates were tested for SARS-CoV-2 and were all found to be negative. Conclusion Overall, with routine prenatal care and preventive measures, pregnant patients and neonates in our study had good outcomes. At this time, there appears to be no evidence of vertical transmission.

Keywords: COVID in pregnancy; COVID-19; COVID-19 in neonates; coronavirus; ethics; fetus; maternal outcomes; neonatal outcomes; synthesis.
 
Back
Top Bottom